20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, demonstrates antihypertensive and organ protective effects in hypertension. We investigated the efficacy of AZL-M to ameliorate metabolic syndrome and kidney damage associated with type 2 diabetes using Zucker diabetic fatty (ZDF) rats.

          Related collections

          Author and article information

          Journal
          Am. J. Hypertens.
          American journal of hypertension
          Oxford University Press (OUP)
          1941-7225
          0895-7061
          Aug 2014
          : 27
          : 8
          Affiliations
          [1 ] Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin;
          [2 ] Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic;
          [3 ] Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin. jdimig@mcw.edu.
          Article
          hpu016
          10.1093/ajh/hpu016
          24598210

          Comments

          Comment on this article